No Data
The actual controller of Taincang (301263.SZ), Sun Weiwen, has pledged 5.64% of his shares.
Taiyingkang (301263.SZ) announced that the company recently received information from its controlling Shareholder and actual controller Sun Weiwen...
Guangdong Taienkang Pharmaceutical (SZSE:301263) Takes On Some Risk With Its Use Of Debt
Taiankang (301263.SZ): Currently, all 200 subjects have been enrolled in the Phase II clinical trial of CKBA ointment.
On November 29, Glonghui reported that Tainkang (301263.SZ) stated on the investor interaction platform that CKBA is a first-in-class (FIC) drug molecule designed and screened by the team of Wang Honglin from Shanghai Jiao Tong University based on the structural modification of the natural product acetyl-11-keto-β-boswellic acid (AKBA) derived from frankincense. The molecular target of CKBA is clear, effective in inhibiting autoreactive CD8+ TRM cells from producing IFN-γ, thus achieving clinical efficacy in treating vitiligo.
Tai En Kang (301263.SZ): Striving to achieve a sales target of 1 billion in the ophthalmology business in the next 3 to 5 years.
Glory Times reported on November 18th that in recent investor relations activities, Thienx (301263.SZ) stated that the company's ophthalmology sector benefits from the good efficacy and product reputation of Voltin, with annual sales revenue stable at around 0.2 billion yuan. With the gradual implementation of self-developed ophthalmic products, the company's ophthalmology sector is expected to continue growing, aiming to achieve a sales target of 1 billion yuan in the next 3 to 5 years.
Tianeng Kang (301263.SZ): Currently, the clinical trial of hydrochloride pilocarpine eye drops is proceeding as planned, aiming to complete the enrollment of all patients by the end of this year.
On November 18, Gelonghui reported that Tainkang (301263.SZ) recently stated in an investor relations event that the company's eye drops containing pilocarpine hydrochloride for treating presbyopia in adults received approval for clinical trials in March 2024, with the first subject enrolled in June 2024. The clinical trials are currently proceeding as planned, and the company will strive to advance the clinical progress, aiming to complete the enrollment of all patients by the end of this year; as of now, there are no similar products approved for sale in the domestic market.
Tianenkang (301263.SZ): Aiming to build Hewei Zhengchang Wan into a well-known product in the gastrointestinal field worth over 1 billion yuan within the next 3 to 5 years.
On November 18, Gelonghui reported that Tai'enkang (301263.SZ) announced in a recent investor relations activity that the company will promote nationwide after obtaining domestic registration approval for the Weizhengchang tablets, further expanding the market share of this variety, and aims to develop it into a well-known product in the gastrointestinal field worth over 1 billion yuan in the next 3 to 5 years.
Cautious Investors Not Rewarding Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Performance Completely
No Data
